AGRX
Agile Therapeutics Inc.
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| 11-01-2018 | 08-03-2018 | 05-07-2018 | 03-12-2018 | 11-06-2017 after market close | 07-28-2017 | 05-08-2017 | |
|---|---|---|---|---|---|---|---|
| Actual EPS | -0.11 | -0.16 | -0.21 | -0.18 | -0.22 | -0.26 | -0.26 |
| Consensus EPS | -0.15 | -0.17 | -0.19 | -0.23 | -0.25 | -0.28 | -0.31 |
| Estimated EPS | -0.15 | -0.17 | -0.19 | -0.23 | -0.25 | -0.28 | -0.31 |
| Number of Estimates | 4 | 4 | 4 | 5 | 5 | 6 | 3 |
| EPS Surprise | $0.04 | $0.01 | -$0.02 | $0.05 | $0.03 | $0.02 | $0.05 |
Stats
Summary
Agile Therapeutics Inc is a women's health specialty pharmaceutical company. The Company is engaged in the development and commercialization of transdermal patch technology for use in contraception products.
Market Cap: 113 Million
Primary Exchange: NASDAQ Global Market
Website: http://www.agiletherapeutics.com
Shares Outstanding: 34.2 Million
Float: 34 Million
Dividend: 0.0 (0.0%)
Beta: 2.183702
Sector: Healthcare
Industry: Drug Manufacturers
Short Interest (Jan 12, 2018): 522 Thousand
Ethical Flags
Longest drawdown: 1014 trading days
From: 2015-04-16 To: 2019-02-20
Lowest Point:
Agile Therapeutics: Positive Study Moves Company Closer To NDA Resubmission
via: SeekingAlpha at 2019-02-13 14:36:36:000
On February 11 th , Agile Therapeutics ( AGRX ) reported topline results from their comparative wear study challenging the adhesion of Twirla matched against Xulane (Figure 1). Once the news hit the wire, AGRX quickly traded up above $1.00 in the premarket but was quickly hit with selling … read more...
Agile Therapeutics: Positive Study Moves Company Closer To NDA Resubmission
via: SeekingAlpha at 2019-02-13 14:36:36:000
On February 11 th , Agile Therapeutics ( AGRX ) reported topline results from their comparative wear study challenging the adhesion of Twirla matched against Xulane (Figure 1). Once the news hit the wire, AGRX quickly traded up above $1.00 in the premarket but was quickly hit with selling … read more...
Agile Therapeutics: Positive Study Moves Company Closer To NDA Resubmission
via: SeekingAlpha at 2019-02-13 14:36:36:000
On February 11 th , Agile Therapeutics ( AGRX ) reported topline results from their comparative wear study challenging the adhesion of Twirla matched against Xulane (Figure 1). Once the news hit the wire, AGRX quickly traded up above $1.00 in the premarket but was quickly hit with selling … read more...
Agile up 22% on positive Twirla data
via: SeekingAlpha at 2019-02-11 08:27:36:000
Thinly traded nano cap Agile Therapeutics (NASDAQ: AGRX ) is up 22% premarket on increased volume in response to its announcement of successful results from a comparative wear study assessing the adhesion of contraceptive patch Twirla (levonorgestrel/ethinyl estradiol transdermal system)… read more...
Agile up 22% on positive Twirla data
via: SeekingAlpha at 2019-02-11 08:27:36:000
Thinly traded nano cap Agile Therapeutics (NASDAQ: AGRX ) is up 22% premarket on increased volume in response to its announcement of successful results from a comparative wear study assessing the adhesion of contraceptive patch Twirla (levonorgestrel/ethinyl estradiol transdermal system)… read more...
Agile Therapeutics: Why You Should Buy Now Before Upcoming Catalysts
via: SeekingAlpha at 2019-01-23 15:15:40:000
It has been a rough couple years for Agile Therapeutics (AGRX), and the share price has taken the brunt of it. The company has been struggling for years to get their once-weekly contraceptive patch, Twirla, approved by the FDA. Twirla has received two CRLs from FDA, with the most recent occurr… read more...
Agile Therapeutics: Why You Should Buy Now Before Upcoming Catalysts
via: SeekingAlpha at 2019-01-23 15:15:40:000
It has been a rough couple years for Agile Therapeutics (AGRX), and the share price has taken the brunt of it. The company has been struggling for years to get their once-weekly contraceptive patch, Twirla, approved by the FDA. Twirla has received two CRLs from FDA, with the most recent occurr… read more...
Agile Therapeutics: Why You Should Buy Now Before Upcoming Catalysts
via: SeekingAlpha at 2019-01-23 15:15:40:000
It has been a rough couple years for Agile Therapeutics (AGRX), and the share price has taken the brunt of it. The company has been struggling for years to get their once-weekly contraceptive patch, Twirla, approved by the FDA. Twirla has received two CRLs from FDA, with the most recent occurr… read more...
Agile Therapeutics advancing Twirla, to refile U.S. marketing application next quarter
via: SeekingAlpha at 2019-01-10 16:25:56:000
Agile Therapeutics (NASDAQ: AGRX ) announces that it expects to complete the comparative wear study aimed at demonstrating non-inferiority of contraceptive patch Twirla to Xulane this quarter followed by its resubmitted marketing application in Q2. More news on: Agile Therapeutics, Inc.,… read more...
Agile Therapeutics advancing Twirla, to refile U.S. marketing application next quarter
via: SeekingAlpha at 2019-01-10 16:25:56:000
Agile Therapeutics (NASDAQ: AGRX ) announces that it expects to complete the comparative wear study aimed at demonstrating non-inferiority of contraceptive patch Twirla to Xulane this quarter followed by its resubmitted marketing application in Q2. More news on: Agile Therapeutics, Inc.,… read more...
Agile Therapeutics advancing Twirla, to refile U.S. marketing application next quarter
via: SeekingAlpha at 2019-01-10 16:25:56:000
Agile Therapeutics (NASDAQ: AGRX ) announces that it expects to complete the comparative wear study aimed at demonstrating non-inferiority of contraceptive patch Twirla to Xulane this quarter followed by its resubmitted marketing application in Q2. More news on: Agile Therapeutics, Inc.,… read more...
Agile meets with FDA on design of study to support Twirla refiling
via: SeekingAlpha at 2018-12-13 16:52:08:000
Agile Therapeutics (NASDAQ: AGRX ) met with the FDA on Tuesday, December 11, to discuss the design of a comparative wear study between contraceptive patch Twirla and Mylan's (NASDAQ: MYL ) Xulane. It will provide more details when it receives the agency's written minutes from the meeting n… read more...
Agile meets with FDA on design of study to support Twirla refiling
via: SeekingAlpha at 2018-12-13 16:52:08:000
Agile Therapeutics (NASDAQ: AGRX ) met with the FDA on Tuesday, December 11, to discuss the design of a comparative wear study between contraceptive patch Twirla and Mylan's (NASDAQ: MYL ) Xulane. It will provide more details when it receives the agency's written minutes from the meeting n… read more...
Agile meets with FDA on design of study to support Twirla refiling
via: SeekingAlpha at 2018-12-13 16:52:08:000
Agile Therapeutics (NASDAQ: AGRX ) met with the FDA on Tuesday, December 11, to discuss the design of a comparative wear study between contraceptive patch Twirla and Mylan's (NASDAQ: MYL ) Xulane. It will provide more details when it receives the agency's written minutes from the meeting n… read more...
Agile meets with FDA on design of study to support Twirla refiling
via: SeekingAlpha at 2018-12-13 16:52:08:000
Agile Therapeutics (NASDAQ: AGRX ) met with the FDA on Tuesday, December 11, to discuss the design of a comparative wear study between contraceptive patch Twirla and Mylan's (NASDAQ: MYL ) Xulane. It will provide more details when it receives the agency's written minutes from the meeting n… read more...
Wainwright bullish on Agile Therapeutics, sees 270% upside
via: SeekingAlpha at 2018-11-29 08:21:26:000
Uber-bull H.C. Wainwright has started coverage of Agile Therapeutics (NASDAQ: AGRX ) with a Buy rating and $3 (270% upside) price target based on the company righting the ship with contraceptive patch Twirla. More news on: Agile Therapeutics, Inc., Healthcare stocks news, Read more …... read more...
Wainwright bullish on Agile Therapeutics, sees 270% upside
via: SeekingAlpha at 2018-11-29 08:21:26:000
Uber-bull H.C. Wainwright has started coverage of Agile Therapeutics (NASDAQ: AGRX ) with a Buy rating and $3 (270% upside) price target based on the company righting the ship with contraceptive patch Twirla. More news on: Agile Therapeutics, Inc., Healthcare stocks news, Read more …... read more...
Wainwright bullish on Agile Therapeutics, sees 270% upside
via: SeekingAlpha at 2018-11-29 08:21:26:000
Uber-bull H.C. Wainwright has started coverage of Agile Therapeutics (NASDAQ: AGRX ) with a Buy rating and $3 (270% upside) price target based on the company righting the ship with contraceptive patch Twirla. More news on: Agile Therapeutics, Inc., Healthcare stocks news, Read more …... read more...
Agile Therapeutics beats by $0.03
via: SeekingAlpha at 2018-11-01 17:23:01:000
Agile Therapeutics (NASDAQ: AGRX ): Q3 GAAP EPS of -$0.11 beats by $0.03. More news on: Agile Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more … read more...
Agile Therapeutics beats by $0.03
via: SeekingAlpha at 2018-11-01 17:23:01:000
Agile Therapeutics (NASDAQ: AGRX ): Q3 GAAP EPS of -$0.11 beats by $0.03. More news on: Agile Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more … read more...
Agile Therapeutics beats by $0.03
via: SeekingAlpha at 2018-11-01 17:23:01:000
Agile Therapeutics (NASDAQ: AGRX ): Q3 GAAP EPS of -$0.11 beats by $0.03. More news on: Agile Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more … read more...
Late-stage data support use of Agile's Twirla in overweight women; shares up 8% premarket
via: SeekingAlpha at 2018-10-24 08:38:04:000
Nano cap Agile Therapeutics (NASDAQ: AGRX ) is up 8% premarket on light volume on the heels of its announcement of additional results from its Phase 3 SECURE study assessing contraceptive patch Twirla (AG200-15). The data were presented at the North American Forum on Family P… read more...
Late-stage data support use of Agile's Twirla in overweight women; shares up 8% premarket
via: SeekingAlpha at 2018-10-24 08:38:04:000
Nano cap Agile Therapeutics (NASDAQ: AGRX ) is up 8% premarket on light volume on the heels of its announcement of additional results from its Phase 3 SECURE study assessing contraceptive patch Twirla (AG200-15). The data were presented at the North American Forum on Family P… read more...
Late-stage data support use of Agile's Twirla in overweight women; shares up 8% premarket
via: SeekingAlpha at 2018-10-24 08:38:04:000
Nano cap Agile Therapeutics (NASDAQ: AGRX ) is up 8% premarket on light volume on the heels of its announcement of additional results from its Phase 3 SECURE study assessing contraceptive patch Twirla (AG200-15). The data were presented at the North American Forum on Family P… read more...
Agile Therapeutics up 62% on development path for Twirla
via: SeekingAlpha at 2018-10-09 11:13:24:000
Nano cap Agile Therapeutics ( AGRX +62.4% ) is up on a healthy 15x surge in volume on the heels of its announcement that the FDA has provided a path forward for contraceptive patch Twirla (levonorgestrel/ethinyl estradiol transdermal system). More news on: Agile Therapeutics, Inc., Myl… read more...
Agile Therapeutics up 62% on development path for Twirla
via: SeekingAlpha at 2018-10-09 11:13:24:000
Nano cap Agile Therapeutics ( AGRX +62.4% ) is up on a healthy 15x surge in volume on the heels of its announcement that the FDA has provided a path forward for contraceptive patch Twirla (levonorgestrel/ethinyl estradiol transdermal system). More news on: Agile Therapeutics, Inc., Myl… read more...
Agile Therapeutics up 62% on development path for Twirla
via: SeekingAlpha at 2018-10-09 11:13:24:000
Nano cap Agile Therapeutics ( AGRX +62.4% ) is up on a healthy 15x surge in volume on the heels of its announcement that the FDA has provided a path forward for contraceptive patch Twirla (levonorgestrel/ethinyl estradiol transdermal system). More news on: Agile Therapeutics, Inc., Myl… read more...
Agile Therapeutics up 62% on development path for Twirla
via: SeekingAlpha at 2018-10-09 11:13:24:000
Nano cap Agile Therapeutics ( AGRX +62.4% ) is up on a healthy 15x surge in volume on the heels of its announcement that the FDA has provided a path forward for contraceptive patch Twirla (levonorgestrel/ethinyl estradiol transdermal system). More news on: Agile Therapeutics, Inc., Myl… read more...
Agile Therapeutics up 62% on development path for Twirla
via: SeekingAlpha at 2018-10-09 11:13:24:000
Nano cap Agile Therapeutics ( AGRX +62.4% ) is up on a healthy 15x surge in volume on the heels of its announcement that the FDA has provided a path forward for contraceptive patch Twirla (levonorgestrel/ethinyl estradiol transdermal system). More news on: Agile Therapeutics, Inc., Myl… read more...
Agile Therapeutics up 62% on development path for Twirla
via: SeekingAlpha at 2018-10-09 11:13:24:000
Nano cap Agile Therapeutics ( AGRX +62.4% ) is up on a healthy 15x surge in volume on the heels of its announcement that the FDA has provided a path forward for contraceptive patch Twirla (levonorgestrel/ethinyl estradiol transdermal system). More news on: Agile Therapeutics, Inc., Myl… read more...
FDA rejects Agile's appeal of Twirla CRL; shares down 41% after hours
via: SeekingAlpha at 2018-07-24 16:35:04:000
Nano cap Agile Therapeutics (NASDAQ: AGRX ) is down 41% after hours in response to its announcement that the Office Director of the FDA's Office of Drug Evaluation III (ODEIII) has affirmed the issuance of the second CRL in December 2017 related to its marketing application for… read more...
FDA rejects Agile's appeal of Twirla CRL; shares down 41% after hours
via: SeekingAlpha at 2018-07-24 16:35:04:000
Nano cap Agile Therapeutics (NASDAQ: AGRX ) is down 41% after hours in response to its announcement that the Office Director of the FDA's Office of Drug Evaluation III (ODEIII) has affirmed the issuance of the second CRL in December 2017 related to its marketing application for… read more...
FDA rejects Agile's appeal of Twirla CRL; shares down 41% after hours
via: SeekingAlpha at 2018-07-24 16:35:04:000
Nano cap Agile Therapeutics (NASDAQ: AGRX ) is down 41% after hours in response to its announcement that the Office Director of the FDA's Office of Drug Evaluation III (ODEIII) has affirmed the issuance of the second CRL in December 2017 related to its marketing application for… read more...
FDA rejects Agile's appeal of Twirla CRL; shares down 41% after hours
via: SeekingAlpha at 2018-07-24 16:35:04:000
Nano cap Agile Therapeutics (NASDAQ: AGRX ) is down 41% after hours in response to its announcement that the Office Director of the FDA's Office of Drug Evaluation III (ODEIII) has affirmed the issuance of the second CRL in December 2017 related to its marketing application for… read more...
FDA rejects Agile's appeal of Twirla CRL; shares down 41% after hours
via: SeekingAlpha at 2018-07-24 16:35:04:000
Nano cap Agile Therapeutics (NASDAQ: AGRX ) is down 41% after hours in response to its announcement that the Office Director of the FDA's Office of Drug Evaluation III (ODEIII) has affirmed the issuance of the second CRL in December 2017 related to its marketing application for… read more...
FDA rejects Agile's appeal of Twirla CRL; shares down 41% after hours
via: SeekingAlpha at 2018-07-24 16:35:04:000
Nano cap Agile Therapeutics (NASDAQ: AGRX ) is down 41% after hours in response to its announcement that the Office Director of the FDA's Office of Drug Evaluation III (ODEIII) has affirmed the issuance of the second CRL in December 2017 related to its marketing application for… read more...
FDA rejects Agile's appeal of Twirla CRL; shares down 41% after hours
via: SeekingAlpha at 2018-07-24 16:35:04:000
Nano cap Agile Therapeutics (NASDAQ: AGRX ) is down 41% after hours in response to its announcement that the Office Director of the FDA's Office of Drug Evaluation III (ODEIII) has affirmed the issuance of the second CRL in December 2017 related to its marketing application for… read more...
An Update On Corium International
via: SeekingAlpha at 2018-06-15 04:44:29:000
Corium International, Inc. ( CORI ) is a biopharmaceutical company developing Corplex Donepezil, a transdermal patch formulation of donepezil for Alzheimer's disease. Donepezil has been tremendously successful in oral form as Aricept, marketed by Pfizer ( PFE ) and Eisai ( OTCPK:ESALF ), reach… read more...
An Update On Corium International
via: SeekingAlpha at 2018-06-15 04:44:29:000
Corium International, Inc. ( CORI ) is a biopharmaceutical company developing Corplex Donepezil, a transdermal patch formulation of donepezil for Alzheimer's disease. Donepezil has been tremendously successful in oral form as Aricept, marketed by Pfizer ( PFE ) and Eisai ( OTCPK:ESALF ), reach… read more...
An Update On Corium International
via: SeekingAlpha at 2018-06-15 04:44:29:000
Corium International, Inc. ( CORI ) is a biopharmaceutical company developing Corplex Donepezil, a transdermal patch formulation of donepezil for Alzheimer's disease. Donepezil has been tremendously successful in oral form as Aricept, marketed by Pfizer ( PFE ) and Eisai ( OTCPK:ESALF ), reach… read more...
An Update On Corium International
via: SeekingAlpha at 2018-06-15 04:44:29:000
Corium International, Inc. ( CORI ) is a biopharmaceutical company developing Corplex Donepezil, a transdermal patch formulation of donepezil for Alzheimer's disease. Donepezil has been tremendously successful in oral form as Aricept, marketed by Pfizer ( PFE ) and Eisai ( OTCPK:ESALF ), reach… read more...
An Update On Corium International
via: SeekingAlpha at 2018-06-15 04:44:29:000
Corium International, Inc. ( CORI ) is a biopharmaceutical company developing Corplex Donepezil, a transdermal patch formulation of donepezil for Alzheimer's disease. Donepezil has been tremendously successful in oral form as Aricept, marketed by Pfizer ( PFE ) and Eisai ( OTCPK:ESALF ), reach… read more...
Institutional Top Ideas Series: Perceptive Advisors
via: SeekingAlpha at 2018-05-24 01:54:56:000
In the last entry of this series, we took a look at top ideas from Opaleye Management, one of the best performing funds we've come across so far thats been growing its AUM at an impressive rate. Going forward, I hope to continue to delve into the portfolios of successful hedge funds … read more...
Institutional Top Ideas Series: Perceptive Advisors
via: SeekingAlpha at 2018-05-24 01:54:56:000
In the last entry of this series, we took a look at top ideas from Opaleye Management, one of the best performing funds we've come across so far thats been growing its AUM at an impressive rate. Going forward, I hope to continue to delve into the portfolios of successful hedge funds … read more...
Institutional Top Ideas Series: Perceptive Advisors
via: SeekingAlpha at 2018-05-24 01:54:56:000
In the last entry of this series, we took a look at top ideas from Opaleye Management, one of the best performing funds we've come across so far thats been growing its AUM at an impressive rate. Going forward, I hope to continue to delve into the portfolios of successful hedge funds … read more...
Institutional Top Ideas Series: Perceptive Advisors
via: SeekingAlpha at 2018-05-24 01:54:56:000
In the last entry of this series, we took a look at top ideas from Opaleye Management, one of the best performing funds we've come across so far thats been growing its AUM at an impressive rate. Going forward, I hope to continue to delve into the portfolios of successful hedge funds … read more...
Institutional Top Ideas Series: Perceptive Advisors
via: SeekingAlpha at 2018-05-24 01:54:56:000
In the last entry of this series, we took a look at top ideas from Opaleye Management, one of the best performing funds we've come across so far thats been growing its AUM at an impressive rate. Going forward, I hope to continue to delve into the portfolios of successful hedge funds … read more...
Agile Therapeutics Is Attempting A Hail Mary Play With A Formal Dispute Resolution
via: SeekingAlpha at 2018-05-21 16:15:11:000
Recently, Agile Therapeutics ( AGRX ) announced that the FDA was not satisfied with the information it had received with respect to the prior CRL. This is not good for the company at all, because it was heavily reliant on moving forward with regulatory approval for Twirla. With limited resou… read more...
Agile Therapeutics Is Attempting A Hail Mary Play With A Formal Dispute Resolution
via: SeekingAlpha at 2018-05-21 16:15:11:000
Recently, Agile Therapeutics ( AGRX ) announced that the FDA was not satisfied with the information it had received with respect to the prior CRL. This is not good for the company at all, because it was heavily reliant on moving forward with regulatory approval for Twirla. With limited resou… read more...
Your Daily Pharma Scoop: Abeona Presents Strong Data, Glaxo Nucala Treatment Benefit, Rocket Pharma's Gene Therapy Data
via: SeekingAlpha at 2018-05-21 10:00:00:000
Analysis focus: ABEO Abeona Therapeutics (ABEO) is down after publishing strongly positive data from its phase 1/2 trial of gene therapy drug candidate ABO-102 in patients with Sanfilippo syndrome type A (MPS III A). MPS III A is a rare inherited disorder characterized by the buildup of … read more...
Your Daily Pharma Scoop: Abeona Presents Strong Data, Glaxo Nucala Treatment Benefit, Rocket Pharma's Gene Therapy Data
via: SeekingAlpha at 2018-05-21 10:00:00:000
Analysis focus: ABEO Abeona Therapeutics (ABEO) is down after publishing strongly positive data from its phase 1/2 trial of gene therapy drug candidate ABO-102 in patients with Sanfilippo syndrome type A (MPS III A). MPS III A is a rare inherited disorder characterized by the buildup of … read more...
Midday Gainers / Losers (05/18/2018)
via: SeekingAlpha at 2018-05-18 12:51:54:000
Gainers: ORPN +31% . MTEX +24% . TYHT +20% . EOLS +18% . QTNT +17% . VLRX +17% . WMLP +16% . AQMS +12% . EGY +13% . SDR +13% . More news on: Bio Blast Pharma, Mannatech, Incorporated, Shineco, Inc., , Stocks on the move, Read more … read more...
Midday Gainers / Losers (05/18/2018)
via: SeekingAlpha at 2018-05-18 12:51:54:000
Gainers: ORPN +31% . MTEX +24% . TYHT +20% . EOLS +18% . QTNT +17% . VLRX +17% . WMLP +16% . AQMS +12% . EGY +13% . SDR +13% . More news on: Bio Blast Pharma, Mannatech, Incorporated, Shineco, Inc., , Stocks on the move, Read more … read more...
Agile Therapeutics down 76% on additional work needed for U.S. approval of Twirla
via: SeekingAlpha at 2018-05-18 10:07:28:000
Thinly traded nano cap Agile Therapeutics ( AGRX -75.9% ) is down on a 20x surge in volume in response to its announcement of FDA feedback related to its second CRL for contraceptive patch Twirla. More news on: Agile Therapeutics, Inc., Healthcare stocks news, Stocks on the move, R… read more...
Agile Therapeutics down 76% on additional work needed for U.S. approval of Twirla
via: SeekingAlpha at 2018-05-18 10:07:28:000
Thinly traded nano cap Agile Therapeutics ( AGRX -75.9% ) is down on a 20x surge in volume in response to its announcement of FDA feedback related to its second CRL for contraceptive patch Twirla. More news on: Agile Therapeutics, Inc., Healthcare stocks news, Stocks on the move, R… read more...
Agile Therapeutics misses by $0.05
via: SeekingAlpha at 2018-03-12 16:25:15:000
Agile Therapeutics (NASDAQ: AGRX ): Q4 EPS of -$0.29 misses by $0.05 . Cash and equivalents of $35.95M Press Release More news on: Agile Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , read more...
Agile Therapeutics misses by $0.05
via: SeekingAlpha at 2018-03-12 16:25:15:000
Agile Therapeutics (NASDAQ: AGRX ): Q4 EPS of -$0.29 misses by $0.05 . Cash and equivalents of $35.95M Press Release More news on: Agile Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , read more...
Corium International: Will This Stellar Growth Company Continue To Deliver Profits?
via: SeekingAlpha at 2018-02-21 03:22:57:000
If the job has been correctly done when a common stock is purchased, the time to sell it is almost never. - The Father of Growth Investing (Philip Fisher) In the past 52-weeks, the shares of Corium International (NASDAQ: CORI ) - a specialty bioscience that focuses on the inno… read more...
Corium International: Will This Stellar Growth Company Continue To Deliver Profits?
via: SeekingAlpha at 2018-02-21 03:22:57:000
If the job has been correctly done when a common stock is purchased, the time to sell it is almost never. - The Father of Growth Investing (Philip Fisher) In the past 52-weeks, the shares of Corium International (NASDAQ: CORI ) - a specialty bioscience that focuses on the inno… read more...
U.S. Biotech/Pharma Sector Daily Observations Letter: Jan. 18, 2018
via: SeekingAlpha at 2018-01-19 12:08:08:000
Market and sector outlook: There has been some market nervousness over the debt ceiling issue. The VIX again rose today and is above 12 level. The 10-bond yield is still rising, extended and ripe for a fall. [[IBB]] and [[XBI]] are likely to make another high to around $116 and $92, resp… read more...
2018 Biotech Investing Theme: Looking For Safety Plays
via: SeekingAlpha at 2018-01-03 13:48:41:000
When I look for biotech stocks to invest in, I typically look for two things. First, does the company's products and/or technology provide a meaningful advantage or advance over the competition. Second, is this a company that might be attractive to others as a potential acquisition target. If … read more...
Your Daily Pharma Scoop: Intercept Updates On NASH Trial, GW Pharmaceuticals Provides Regulatory Update, Odonate Initiates Trial
via: SeekingAlpha at 2017-12-30 13:35:25:000
Analysis of top Seeking Alpha coverage: Intercept Today we will discuss an update from Intercept Pharmaceuticals ( ICPT ) with regards to its REVERSE trial in NASH patients with compensated cirrhosis. Intercept had earlier guided for commencing the Phase 3 trial by the end of this year… read more...
Your Daily Pharma Scoop: Portola BLA Review Process Delayed, DelMar Soars, Alexion Gets Nod For Soliris In Japan
via: SeekingAlpha at 2017-12-28 01:42:08:000
Analysis of top Seeking Alpha coverage: Portola Today we will discuss the implications of the delay in the review of Portolas ( PTLA ) AndexXa BLA. The news sent PTLA shares down more than 10% on Tuesday. Portola closed 10.68% lower on Tuesday at $49. Despite the sell-off on Tu… read more...
Biotech Analysis Central Pharma News: Agile CRL, Roche's Purchase, Mallinckrodt's Major Buy
via: SeekingAlpha at 2017-12-28 00:14:13:000
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Agile Therapeutics Receives CRL For Twirla News: Recently, Agile Therapeutics ( AGRX ) received a complete response letter ((CRL)) for its contracep… read more...
Agile Therapeutics: Sell-Off Post CRL Makes It Worth A Look
via: SeekingAlpha at 2017-12-27 03:01:44:000
For Agile Therapeutics ( AGRX ) shareholders, 2017 is ending pretty much the way it began. At the start of the year, AGRX saw a huge drop after the company announced results from its Phase 3 SECURE study. While the company noted in its press release that the top-line results were pos… read more...
Biotech Forum Daily Digest: Behind Fate's Rally
via: SeekingAlpha at 2017-12-26 10:06:06:000
If this country is ever demoralized, it will come from trying to live without work . Abraham Lincoln First of all, I hope the entire Seeking Alpha community had a joyous holiday season with friends and family. May 2018 bring good health and prosperity to you and yours. … read more...
Your Daily Pharma Scoop: Amgen Plans To Bring Back Cash, Roche Acquires Ignyta, Agile Tumbles On CRL
via: SeekingAlpha at 2017-12-26 04:23:59:000
Analysis of top Seeking Alpha coverage: Amgen Today we will discuss Amgens ( AMGN ) plans to repatriate some of its cash holdings outside the U.S. In a SEC filing, Amgen noted that it expects to incur $6-$6.5 billion in tax expenses over time as it brings the cash back into the U… read more...
Midday Gainers / Losers
via: SeekingAlpha at 2017-12-22 12:46:05:000
Gainers: SGLB +213% . RXDX +72% . CERC +22% . ADOM +23% . WPRT +16% . CHCI +18% . FATE +13% . PRTY +14% . LJPC +13% . More news on: Sigma Labs, Inc., Ignyta, Inc., Cerecor, Stocks on the move, Read more … read more...
Biotech Forum Daily Digest: Synergy's CEO Leaves, Shareholders Cheer!
via: SeekingAlpha at 2017-12-22 11:51:39:000
I love deadlines. I love the whooshing noise they make as they go by . Douglas Adams, The Salmon of Doubt Another trading day, another record close for the major indices on Thursday. While the biotech sector is more than five percent off from its recent highs to end th… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|